8-K: Silexion Therapeutics Faces Nasdaq Delisting Risk Due to Low Share Price

Silexion Therapeutics Corp has received a notice from Nasdaq for failing to maintain the minimum $1.00 share price, putting its listing at risk.

Summary

• Silexion Therapeutics Corp received a deficiency letter from Nasdaq because its share price fell below $1.00 for 30 consecutive business days.
• The company has until April 28, 2025, to regain compliance by having its share price close at or above $1.00 for at least 10 consecutive business days.
• If compliance is not achieved by this date, Silexion may be granted a second 180-day period if it applies to transfer to the Nasdaq Capital Market and meets other listing requirements.
• The company is considering a reverse share split, with a proposed ratio between 1-for-10 and 1-for-20, to be voted on at an extraordinary general meeting on November 12, 2024.
• There is no guarantee that the reverse share split will be approved or that it will successfully raise the share price to meet Nasdaq requirements.
• Failure to regain compliance could lead to delisting from the Nasdaq, although the company can appeal such a decision.

Sentiment

Score: 3

Explanation: The document indicates a significant negative event (potential delisting) and uncertainty about the company's ability to regain compliance. The proposed reverse split is a reactive measure, not a positive development.

Positives

• The company has been granted a grace period until April 28, 2025, to regain compliance.
• Silexion has the option to apply for a second 180-day compliance period by transferring to the Nasdaq Capital Market.
• The company is actively considering a reverse share split to address the share price issue.

Negatives

• The company's share price has fallen below the minimum $1.00 required for continued listing on the Nasdaq.
• There is no guarantee that the proposed reverse share split will be approved by shareholders.
• Even if approved, the reverse share split may not be sufficient to regain compliance.
• The company faces the risk of delisting from the Nasdaq if it fails to regain compliance.

Risks

• The company faces the risk of delisting from the Nasdaq if it does not regain compliance with the minimum share price requirement.
• There is no guarantee that the proposed reverse share split will be approved or effective.
• The company may not be granted a second extension to regain compliance.
• Delisting could negatively impact the company's ability to raise capital and its share price.

Future Outlook

The company intends to actively monitor its share price and consider available options, including a reverse share split, to regain compliance with Nasdaq listing rules. There is no guarantee of success.

Management Comments

• The company intends to actively monitor the closing bid price of its ordinary shares and will consider available options to resolve the deficiency and regain compliance with Rule 5450(a)(1).

Industry Context

This situation is not uncommon for companies that experience a decline in their share price. Many companies have faced similar delisting notices and have had to implement strategies such as reverse share splits to regain compliance.

Comparison to Industry Standards

• Many biotech companies, especially those in the early stages of development, can experience share price volatility and may face similar challenges with maintaining listing requirements.
• Reverse share splits are a common strategy used by companies to increase their share price and avoid delisting, but their success is not guaranteed.
• Companies like Silexion are often compared to other small-cap biotech firms that are also working on novel therapies and may have similar financial profiles and market capitalization.

Stakeholder Impact

• Shareholders face the risk of further share price decline and potential delisting.
• Employees may experience uncertainty about the company's future.
• Creditors may be concerned about the company's financial stability.

Next Steps

• The company will monitor its share price.
• The company will hold an extraordinary general meeting on November 12, 2024, to vote on a proposed reverse share split.
• The company will consider other options to regain compliance with Nasdaq listing rules.
• The company may apply to transfer to the Nasdaq Capital Market if necessary.

Key Dates

Keywords

Nasdaq, delisting, share price, compliance, reverse share split, listing rule, Silexion Therapeutics, SLXN, SLXNW